Mixed Treatment Comparison of Adverse Events for BG-12, Glatiramer, and Teriflunomide for the Treatment of Relapsing Forms of Multiple Sclerosis

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.2238
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pnd60 - Cost-Effectiveness of Teriflunomide for the Treatment of Relapsing-Remitting Multiple Sclerosis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd72 - Cost-Minimization Analysis of Teriflunomide and Dimethyl Fumarate for Treatment of Relapsing-Remitting Forms of Multiple Sclerosis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-Remitting Multiple Sclerosis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Teriflunomide in the Treatment of Multiple Sclerosis: Current Evidence and Future Prospects

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2014English

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Intravenous Immunoglobulin G for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis

European Journal of Neurology
Neurology
2002English

Adverse Events With Fatal Outcome Associated With Alemtuzumab Treatment in Multiple Sclerosis

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2019English

Teriflunomide Treatment for Multiple Sclerosis Modulates T Cell Mitochondrial Respiration With Affinity-Dependent Effects

Science Translational Medicine
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy